Journal: Genes & Diseases

Article Title: Blockade of co-inhibitory receptor immune checkpoint protein TIM3/CD366 augments the anti-cancer activity of CAR-T therapy in solid tumors: An ovarian cancer example

doi: 10.1016/j.gendis.2025.101978

Figure Lengend Snippet: Specific IFN-γ and TNF-α release of T lymphocytes transduced with TIM-3-silenced HER2-specific chimeric antigen receptor (CAR) or HER2-specific CAR. (A, B) TIM-3-silenced CAR-T cells and control T cells were co-incubated with Galectin-9 + or Galectin-9 – SKOV3 tumor cells (E:T ratio 5:1 or 10:1). At 20 h after coculture, a specific enzyme-linked immunosorbent assay was used to analyze the supernatant for IFN-γ cytokine-release. Results were presented as mean ± standard deviation. (C, D) The detection of TNF-α in the same culture supernatant. Results were presented as mean ± standard deviation. ∗ P < 0.05 and ∗∗ P < 0.01.

Article Snippet: Human cervical cancer cell line HeLa, lentivirus packaging cell line HEK 293TD, and human ovarian cancer cell line SKOV3 were purchased from American Type Culture Collection (Manassas, Virginia, USA) and cultured in Dulbecco's modified Eagle's medium (Invitrogen, Grand Island, New York) supplemented with 10% heat-inactivated fetal bovine serum.

Techniques: Transduction, Control, Incubation, Enzyme-linked Immunosorbent Assay, Standard Deviation

Journal: Genes & Diseases

Article Title: Blockade of co-inhibitory receptor immune checkpoint protein TIM3/CD366 augments the anti-cancer activity of CAR-T therapy in solid tumors: An ovarian cancer example

doi: 10.1016/j.gendis.2025.101978

Figure Lengend Snippet: TIM-3 silencing augmented the anti-tumor activity of chimeric antigen receptor-T (CAR-T) cells in vivo . 2 × 10 6 SKOV3 tumor cells expressing luciferase were intraperitoneally inoculated in a xenograft mouse model, and 7 days after inoculation, the 2 × 10 6 HER2-specific CAR-T kdTim-3 cells or CAR-T cells, or untreated T cells were intraperitoneally administered. (A, B) Tumor growth was monitored using an in vivo imaging system. (C) Survival curve of 80-day post-treatment. ∗ P < 0.05 and ∗∗ P < 0.01.

Article Snippet: Human cervical cancer cell line HeLa, lentivirus packaging cell line HEK 293TD, and human ovarian cancer cell line SKOV3 were purchased from American Type Culture Collection (Manassas, Virginia, USA) and cultured in Dulbecco's modified Eagle's medium (Invitrogen, Grand Island, New York) supplemented with 10% heat-inactivated fetal bovine serum.

Techniques: Activity Assay, In Vivo, Expressing, Luciferase, In Vivo Imaging

Journal: Translational Oncology

Article Title: Integrating spatial and single-cell transcriptomics via machine learning to characterize efferocytosis in hepatocellular carcinoma prognosis and immunotherapy

doi: 10.1016/j.tranon.2026.102801

Figure Lengend Snippet: Identification and multi-level validation of TPI1 as a pivotal prognostic driver. (A) Lollipop chart showing the selection frequency of feature genes across 101 machine learning models, identifying TPI1 as a high-frequency core gene. (B) Univariate Cox regression analysis of candidate genes; TPI1 exhibited the most substantial Hazard Ratio (HR), characterizing it as a preeminent risk factor. (C) Expression profiling of TPI1 across malignant versus paracancerous tissues within the TCGA-LIHC discovery cohort (upper) and GSE14520 validation cohort (lower). (D) Kaplan-Meier overall survival curves comparing patients with high and low TPI1 expression in the TCGA-LIHC (top) and GSE14520 (bottom) cohorts. (E) Relative mRNA expression levels of TPI1 in the immortalized human hepatocyte line (MIHA) and HCC cell lines (Huh7, SMMC-7721) determined by RT-qPCR. (F) Representative Western blot images (left) and densitometric quantification (right) of TPI1 protein levels in MIHA, Huh7, and SMMC-7721 cells. GAPDH served as the internal loading control. Data are expressed as mean ± SD. ** P < 0.01, *** P < 0.001.

Article Snippet: The human HCC cell lines (Huh7 and SMMC-7721) and the immortalized human hepatocyte line MIHA were procured from Procell Life Science & Technology Co., Ltd. (Wuhan, China).

Techniques: Biomarker Discovery, Selection, Expressing, Quantitative RT-PCR, Western Blot, Control